Holen Sie sich die Stockscreener-App
11.25
1.72%
0.19
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$11.06
Offen:
$11.1
24-Stunden-Volumen:
8.72M
Relative Volume:
1.03
Marktkapitalisierung:
$13.43B
Einnahmen:
$15.05B
Nettoeinkommen (Verlust:
$-883.30M
KGV:
-15.20
EPS:
-0.74
Netto-Cashflow:
$1.89B
1W Leistung:
+4.17%
1M Leistung:
-0.71%
6M Leistung:
-4.01%
1J Leistung:
-15.16%
1-Tages-Spanne:
$11.01
$11.31
1-Wochen-Bereich:
$10.74
$11.31
52-Wochen-Spanne:
$9.925
$13.62
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
11.25 | 13.43B | 15.05B | -883.30M | 1.89B | -0.74 |
|
ZTS
Zoetis Inc
|
160.46 | 71.85B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.08 | 45.58B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.06 | 44.58B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.74 | 19.18B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
128.60 | 13.67B | 612.78M | -86.37M | -62.91M | -0.87 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
What's in the Cards for Viatris Stock This Q4 Earnings? - Yahoo Finance
Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034 - GlobeNewswire Inc.
Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline - Yahoo Finance
50 Years of Service: From Milkman’s Son to Advancing Access to Medicines - CSRwire.com
Viatris Inc.: Is It Time to Sell VTRS Stock Amid Declining Fundamentals?News and Statistics - IndexBox, Inc.
HAGENS BERMAN Alerts Viatris (VTRS) Investors to Pending Securities Fraud Class Action, Encourages Investors with Substantial Losses to Contact Firm’s Attorneys - ACCESS Newswire
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris Inc. stock falls Monday, underperforms market - MarketWatch
Hypovolemic Shock Market 2024-2031 | Pfizer Inc, Viatris Inc, - openPR
YieldBoost Viatris From 4.5% To 11.1% Using Options - Nasdaq
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Pediatric Healthcare Industry May See a Big Move |Boehringer Ingelheim, Glaxosmithkline, Viatris - openPR
3 Generic Drug Stocks to Watch - Morningstar
Viatris Stock Outlook: Is Wall Street Bullish or Bearish? - Nasdaq
Viatris Stock Outlook: Is Wall Street Bullish Or Bearish? - Barchart
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - Nasdaq
Here's What to Expect From Viatris' Next Earnings Report - MSN
Viatris to Report Fourth Quarter and Full Year 2024 Financial Re - GuruFocus.com
Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 – Company Announcement - Financial Times
BofA Adjusts Price Target on Viatris to $11 From $12 -February 03, 2025 at 10:50 am EST - Marketscreener.com
Viatris Financial Results: Key Q4 and 2024 Performance Data Coming February 27 - StockTitan
Viatris And Idorsia Forge Global Partnership For Breakthrough Heart Attack Treatments - MSN
VTRS: 3 Hidden Bargains in the Healthcare Sector - StockNews.com
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
6 New 4-Star Stocks - Morningstar
Chris Davis Reduces Stake in Viatris Inc: A Strategic Portfolio Adjustment - GuruFocus.com
Viatris: Consolidate In 2025, Win In 2026How 'Phase 2' Of Business Plan May Play Out - Seeking Alpha
Here's What To Expect From Viatris' Next Earnings Report - Barchart
Lidocaine Patches Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Viatris Inc., Galen - EIN News
Shell says head of downstream and renewables division Vigeveno to step down -January 23, 2025 at 02:27 am EST - Marketscreener.com
Taxanes Market: Projected Growth Trends through 2031 | Pfizer - openPR
Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? - Insider Monkey
EU Antitrust Chief Ribera: Consumer Protections Remain Top Priority - PYMNTS.com
Is Viatris Inc. (VTRS) Among Wednesday’s Losers? - MSN
Viatris Launch Plans Continue To Drag On, But Confidence High On Quartet - News & Insights
Viatris Inc. stock falls Wednesday, underperforms market - MarketWatch
Viatris Inc (VTRS) Stock Price Down 4.56% on Jan 15 - GuruFocus.com
Is Viatris (VTRS) a Great Value Stock Right Now? - Yahoo Finance
Viatris To Present At J.P. Morgan Healthcare Conference; Webcast At 11:15 AM ET - Nasdaq
Viatris firm in Cork paid $4bn of dividends as sales fell ahead of announced plant closure - Business Post
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical Trials Progress and Therapeutic Advancements | Sanofi SA, Eli Lilly & Company, Viatris Inc., Novartis AG, GlaxoSmithKline, Roche - Barchart
Systemic Lupus Erythematosus Pipeline Report 2024: Clinical - openPR
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
1.53%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):